Immune responses to polysaccharides: Lessons from humans and mice

Vaccine

Volumn 26, Issue 3, 2008, Pages 292-300

  González Fernández, África ^a   Faro, Jose ^a,b   Fernández, Carmen ^c  

^a UNIVERSITY OF VIGO   (Spain)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Negative memory; Polysaccharides; Vaccines

Indexed keywords

ANTIBIOTIC AGENT; CHOLERA TOXIN; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; T CELL DEPENDENT VACCINE; T CELL INDEPENDENT TYPE 2 VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; BACTERIAL INFECTION; BIOLOGICAL MODEL; CHILD CARE; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE RESPONSE; INFECTION RISK; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; INFANT; INFANT, NEWBORN; MENINGOCOCCAL INFECTIONS; MICE; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTIONS; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 37649011029     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.042     Document Type: Review

References (94)

1. Lesinski G.B., and Westerink M.A. Vaccines against polysaccharide antigens. Curr Drug Targets Infect Disord 1 (2001) 325-334
2. Vos Q., Lees A., Wu Z.Q., Snapper C.M., and Mond J.J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176 (2000) 154-170
3. Obukhanych T.V., and Nussenzweig M.C. T-independent type II immune responses generate memory B cells. J Exp Med 203 (2006) 305-310
4. MacLennan I.C. Germinal centers. Annu Rev Immunol 12 (1994) 117-139
5. Lucas A.H., Apicella M.A., and Taylor C.E. Carbohydrate moieties as vaccine candidates. Clin Infect Dis 41 (2005) 705-712
6. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., and Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280 (1998) 1685-1689
7. Anderson E.L., Bowers T., Mink C.M., Kennedy D.J., Belshe R.B., Harakeh H., et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 62 (1994) 3391-3395
8. Goldblatt D., Borrow R., and Miller E. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis 185 (2002) 397-400
9. Zegers B.J., van der Giessen M., Reerink-Brongers E.E., and Stoop J.W. The serum IgG subclass levels in healthy infants of 13-62 weeks of age. Clin Chim Acta 101 (1980) 265-269
10. Garty B.Z., Ludomirsky A., Danon Y.L., Peter J.B., and Douglas S.D. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1 (1994) 667-669
11. Aucouturier P., Berthier M., Bonneau D., and Preud'homme J.L. Serum levels of IgG subclasses in the normal child. Evaluation by an immunoenzymatic method using monoclonal antibodies. Arch Fr Pediatr 45 (1988) 255-258
12. Barrett D.J., and Ayoub E.M. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 63 (1986) 127-134
13. Candy D., Davies E.G., and Ross E. Clinical paediatrics and child health (2001), Saunders (WB) Co. Ltd., London
14. Finocchi A., Angelini F., Chini L., Di Cesare S., Cancrini C., Rossi P., et al. Evaluation of the relevance of humoral immunodeficiencies in a pediatric population affected by recurrent infections. Pediatr Allergy Immunol 13 (2002) 443-447
15. Sills R.H. Splenic function: physiology and splenic hypofunction. Crit Rev Oncol Hematol 7 (1987) 1-36
16. Melles D.C., and de Marie S. Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med 62 (2004) 45-52
17. Castagnola E., and Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol 71 (2003) 319-326
18. Steiniger B., Timphus E.M., and Barth P.J. The splenic marginal zone in humans and rodents: an enigmatic compartment and its inhabitants. Histochem Cell Biol 126 (2006) 641-648
19. Timens W., Boes A., Rozeboom-Uiterwijk T., and Poppema S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 143 (1989) 3200-3206
20. Breukels M.A., Zandvoort A., Rijkers G.T., Lodewijk M.E., Klok P.A., Harms G., et al. Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines. Scand J Immunol 61 (2005) 322-328
21. Cobb B.A., Wang Q., Tzianabos A.O., and Kasper D.L. Polysaccharide processing and presentation by the MHCII pathway. Cell 117 (2004) 677-687
22. Faro J. Modulación meningocócica de la respuesta inmunitaria a epítopos de Neisseria meningitidis. Doctoral Thesis. Universidad de Santiago de Compostela; 1986.
23. Levine O.S., O'Brien K.L., Knoll M., Adegbola R.A., Black S., Cherian T., et al. Pneumococcal vaccination in developing countries. Lancet 367 (2006) 1880-1882
24. Danzig L. Meningococcal vaccines. Pediatr Infect Dis J 23 (2004) S285-S292
25. Soriano-Gabarro M., Stuart J.M., and Rosenstein N.E. Vaccines for the prevention of meningococcal disease in children. Semin Pediatr Infect Dis 13 (2002) 182-189
26. Pollabauer E.M., Petermann R., and Ehrlich H.J. Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum Vaccin 1 (2005) 131-139
27. ACIP. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49 RR-7 (2000) 1-10
28. Cook I.F., Pond D., and Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 25 (2007) 4767-4774
29. Lepow M.L., Goldschneider I., Gold R., Randolph M., and Gotschlich E.C. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 60 (1977) 673-680
30. Borrow R., Joseph H., Andrews N., Acuna M., Longworth E., Martin S., et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 19 (2000) 1129-1132
31. Granoff D.M., Gupta R.K., Belshe R.B., and Anderson E.L. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 178 (1998) 870-874
32. Vu D.M., de Boer A.W., Danzig L., Santos G., Canty B., Flores B.M., et al. Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol 13 (2006) 605-610
33. Lakshman R., Burkinshaw R., Choo S., and Finn A. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults. Vaccine 20 (2002) 3778-3782
34. Position paper W.H.O. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec 77 (2002) 331-339
35. Schneerson R., Barrera O., Sutton A., and Robbins J.B. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 152 (1980) 361-376
36. 197. Infect Immun 39 (1983) 233-238
37. Beuvery E.C., van Delft R.W., Miedema F., Kanhai V., and Nagel J. Immunological evaluation of meningococcal Group C polysaccharide-tetanus toxoid conjugate in mice. Infect Immun 41 (1983) 609-617
38. Rubinstein L.J., Garcia-Ojeda P.A., Michon F., Jennings H.J., and Stein K.E. Murine immune responses to Neisseria meningitides group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. Infect Immun 66 (1998) 5450-5456
39. Larrauri A., Cano R., Garcia M., and Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23 (2005) 4097-4100
40. Oosterhuis-Kafeja F., Beutels P., and Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25 (2007) 2194-2212
41. WHO position paper. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record. Wkly Epidemiol Rec 2006; 81:445-52.
42. Lockhart S.P., Hackell J.G., and Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev Vaccines 5 (2006) 553-564
43. Barocchi M.A., Censini S., and Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine 25 (2007) 2963-2973
44. Fletcher M.A., and Fritzell B. Brief review of the clinical effectiveness of PREVENAR against otitis media. Vaccine 25 (2007) 2507-2512
45. Poehling K.A., Szilagyi P.G., Grijalva C.G., Martin S.W., LaFleur B., Mitchel E., et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119 (2007) 707-715
46. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118 (2006) 865-873
47. Jodar L., Feavers I.M., Salisbury D., and Granoff D.M. Development of vaccines against meningococcal disease. Lancet 359 (2002) 1499-1508
48. Temime L., and Dab W. Pneumococcal vaccination: expected benefits in adults. Rev Med Interne 28 (2007) 9-15
49. Powers D.C., Anderson E.L., Lottenbach K., and Mink C.M. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 173 (1996) 1014-1018
50. Abraham-Van P.B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 22 (2004) 1362-1371
51. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
52. De Wals P., Trottier P., and Pepin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 24 (2006) 3500-3504
53. Weller S., Reynaud C.A., and Weill J.C. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol 26 (2005) 85-89
54. Auckland C., Gray S., Borrow R., Andrews N., Goldblatt D., Ramsay M., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 194 (2006) 1745-1752
55. Choo S., Zuckerman J., Goilav C., Hatzmann E., Everard J., and Finn A. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 18 (2000) 2686-2692
56. Beuvery E.C., van Delft R.W., Miedema F., Kanhai V., and Nagel J. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infect Immun 41 (1983) 609-617
57. Rubinstein L.J., García-Ojeda P.A., Michon F., Jennings H.J., and Stein K.J. Murine immune responses to Neisseria meningitidis group c capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. Infect Immun 66 (1998) 5450-5456
58. Shriner A.K., Smithson S.L., Prinz D.M., Rabquer B., Khuder S., Goomber R., et al. Comparison of the human immune response to conjugate and polysaccharide pneumococcal vaccination using a reconstituted SCID mouse model. Vaccine 24 (2006) 7197-7203
59. Sabirov A., and Metzger D.W. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 24 (2006) 5584-5592
60. Steinhoff M.C. Pneumococcal vaccine animal model consensus group. Animal models for protein pneumococcal vaccine evaluation: a summary. Vaccine 25 (2007) 2465-2470
61. Adderson E.E., Shackelford P.G., Insel R.A., Quinn A., Wilson P.M., and Carroll W.L. Immunoglobulin light chain variable region gene sequences for human antibodies to Haemophilus influenzae type b capsular polysaccharide are dominated by a limited number of V kappa and V lambda segments and VJ combinations. J Clin Invest 89 (1992) 729-738
62. Zhou J., Lottenbach K.R., Barenkamp S.J., Lucas A.H., and Reason D.C. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect Immun 70 (2002) 4083-4091
63. Koppel E.A., Wieland C.W., van den Berg V.C., Litjens M., Florquin S., van Kooyk Y., et al. Specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for defense against pulmonary Streptococcus pneumoniae infection. Eur J Immunol 35 (2005) 2962-2969
64. Galustian C., Park C.G., Chai W., Kiso M., Bruening S.A., Kang Y.S., et al. High- and low-affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and langerin. Int Immunol 16 (2004) 853-866
65. Fernández C., and Möller G. Serum antibody and cellular immune response in mice to dextran B512. Cell Immunol 131 (1990) 41-51
66. Sverremark E., Fernández C., and Möller G. Anti-IgM-Ficoll conjugates activate B cells from CBA but not CBA/N mice. Cell Immunol 155 (1994) 323-334
67. Sikder S.K., Akolkar P.N., Kaladas P.M., Morrison S.L., and Kabat E.A. Sequences of variable regions of hybridoma antibodies to alpha (1-6) dextran in BALB/c and C57BL/6 mice. J Immunol 135 (1985) 4215-4221
68. Fernández C. Genetic mechanism for dominant VH gene expression. The VHB512 gene. J Immunol 149 (1992) 2328-2336
69. Fernández C., and Moller G. Immunological unresponsiveness to native dextran B512 in young animals of dextran high responder strains is due to lack of Ig receptors expression. Evidence for a nonrandom expression of V-genes. J Exp Med 147 (1978) 645-655
70. Wood C., Fernández C., and Möller G. Ontogenic development of the suppressed secondary response to native dextran. Scand J Immunol 16 (1982) 287-292
71. Lundkvist I., Holmberg D., Ivars F., and Coutinho A. The immune response to bacterial dextrans. Part III. Ontogenic development and strain distribution of specific clonal precursors. Eur J Immunol 16 (1986) 957-962
72. Fernández C., and Möller G. A primary immune response to dextran B512 is followed by a period of antigen-specific immunosuppression caused by autoanti-idiotypic antibodies. Scand J Immunol 11 (1980) 53-62
73. Fernández C., and Möller G. Antigen-induced strain-specific autoantiidiotypic antibodies modulate the immune response to dextran B 512. Proc Natl Acad Sci USA 76 (1979) 5944-5947
74. Möller G., and Fernández C. Immunological tolerance to the thymus-independent antigen dextran can be abrogated by thymus-dependent dextran conjugates: evidence against clonal deletion as the mechanism of tolerance induction. Scand J Immunol 8 (1978) 29-37
75. Faro J., Seoane R., Puentes E., Martinez U.F., and Regueiro B.J. Immunoresponses to Neisseria meningitidis epitopes: primary versus secondary antiphosphorylcholine responses. Infect Immun 48 (1985) 428-432
76. Seppala I., and Makela O. Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling. J Immunol 143 (1989) 1259-1264
77. Fernández C., and Sverremark E. Immune responses to bacterial polysaccharides: terminal epitopes are more immunogenic than internal structures. Cell Immunol 153 (1994) 67-78
78. Faro J., Seoane R., Eiras A., Lareo I., Couceiro J., and Regueiro B.J. Immunoresponses to Neisseria meningitidis epitopes: suppression of secondary response to phosphorylcholine is carrier specific. Infect Immun 51 (1986) 224-232
79. Faro J., Seoane R., Lareo I., Eiras A., Schiller M., and Regueiro B.J. Immunoresponses to Neisseria meningitidis epitopes: in vivo analysis of immunocompetent cells involved in suppression of secondary response to phosphorylcholine. Med Microbiol Immunol 176 (1987) 289-303
80. Sverremark E., and Fernández C. Unresponsiveness following immunization with the T-cell-independent antigen dextran B512. Can it be abrogated?. Immunology 95 (1998) 402-408
81. Sánchez M., Lindroth K., Sverremark E., González-Fernández A., and Fernández C. The response in old mice: positive and negative immune memory after priming in early age. Int Immunol 13 (2001) 1213-1221
82. Lindroth K., Mastache E.F., Roos I., González-Fernández A., and Fernández C. Understanding thymus-independent antigen-induced reduction of thymus-dependent immune responses. Immunology 112 (2004) 413-419
83. Southern J., Deane S., Ashton L., Borrow R., Goldblatt D., Andrews N., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 11 (2004) 1100-1104
84. Sverremark E., and Fernández C. Germinal center formation following immunization with the polysaccharide dextran B512 is substantially increased by cholera toxin. Int Immunol 10 (1998) 851-859
85. Agren L., Sverremark E., Ekman L., Schön K., Löwenadler B., Fernandez C., et al. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J Immunol 164 (2000) 6276-6286
86. Wang D., Wells S.M., Stall A.M., and Kabat E.A. Reaction of germinal centers in the T-cell-independent response to the bacterial polysaccharide alpha(1->6)dextran. Proc Natl Acad Sci USA 91 (1994) 2502-2506
87. Haas K.M., Poe J.C., Steeber D.A., and Tedder T.F. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23 (2005) 7-18
88. Alugupalli K.R., Leong J.M., Woodland R.T., Muramatsu M., Honjo T., and Gerstein R.M. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 21 (2004) 379-390
89. Phan T.G., Paus D., Chan T.D., Turner M.L., Nutt S.L., Basten A., et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med 203 (2006) 2419-2424
90. O'Connor B.P., Vogel L.A., Zhang W., Loo W., Shnider D., Lind E.F., et al. Imprinting the fate of antigen-reactive B cells through the affinity of the B-cell receptor. J Immunol 177 (2006) 7723-7732
91. Lindroth K., Fernández C. The role of Blim-1 in the GC reaction. Differential expression of Blimp-1 upon immunization with TD and TI antigens. Immunol Lett 2007; Aug 23; (Epub ahead of print).
92. Kabelitz D. Expression and function of toll-like receptors in T lymphocytes. Curr Opin Immunol 19 (2007) 39-45
93. Lycke N. Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 5 (2005) 591-597
94. Helgeby A., Robson N.C., Donachie A.M., Beackock-Sharp H., Lövgren K., Schön K., et al. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol 176 (2006) 3697-3706